IMNN Stock — Imunon Inc.: Cash, EV, Pipeline

Share price

$1.36

Market cap

$7.6M

Cash

$6.9M

Enterprise value

$0.7M

Balance sheet

Cash	$6.9M
Debt	$0.0M
Net cash	$6.9M
Enterprise value	$0.7M
Basic shares	4.7M shares
Fully diluted shares	8.5M shares
Fully diluted market cap	$11.6M
Cash per share	$1.46

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading IMNN daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Aug 11 - Sep 22	Paclitaxel	Phase 1/2	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	—
Dec 12, 2032 - Jan 23, 2033	Paclitaxel	Phase 3	Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

IMNN-001

Phase 3 · Active Modality: DNA plasmid immunotherapy (TheraPlas)

Target IL-12

Partnerships Break Through Cancer (Phase 2 minimal residual disease study collaboration)

Indications

Advanced ovarian cancer (Phase 3)

Status note Pivotal Phase 3 OVATION 3 trial in newly diagnosed advanced ovarian cancer ongoing; iDMC recommended continuation without modification in June 2026. FDA Fast Track designated. Phase 2 OVATION 2 completed.

IMNN-101

Phase 1 · Active Modality: DNA vaccine (PlaCCine)

Target SARS-CoV-2 antigens

Indications

COVID-19 (seasonal booster) (Phase 1)

Status note Plasmid vector encoding multiple SARS-CoV-2 antigens. Phase 1 proof-of-concept study completed; company has paused further development and intends to seek partnership/business development opportunities.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)
Lead indication	Epithelial Ovarian Cancer
Lead phase	Phase 3
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06915025	Phase 3	Recruiting	Sponsor	Imunon	—	Epithelial Ovarian Cancer; Ovarian Cancer; Fallopian Tube Cancer	—
NCT05739981	Phase 1/2	Recruiting	Sponsor	Imunon	—	Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	—
NCT03393884	Phase 1/2	Active, not recruiting	Sponsor	Imunon	—	Epithelial Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Imunon on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

IMNN — Imunon Inc.